%0 Journal Article
%T Group 3 Pulmonary Hypertension: A Review of Diagnostics and Clinical Trials.
%A Shioleno AM
%A Ruopp NF
%J Clin Chest Med
%V 42
%N 1
%D 03 2021
%M 33541617
%F 4.967
%R 10.1016/j.ccm.2020.11.006
%X Group 3 pulmonary hypertension (PH) is a known sequelae of chronic lung disease. Diagnosis and classification can be challenging in the background of chronic lung disease and often requires expert interpretation of numerous diagnostic studies to ascertain the true nature of the PH. Stabilization of the underlying lung disease and adjunctive therapies such as oxygen remain the mainstays of therapy, as there are no Food and Drug Administration-approved therapies for group 3 PH. Referral to PH centers for individualized management and clinical trial enrollment is paramount.